ArticleNeurosurgical review2025
Arterial wall enhancement on high-resolution vessel-wall MRI correlates with stenosis burden and large-artery atherosclerosis subtype in ischemic stroke.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial atherosclerosis (ICAS) is a leading cause of ischemic stroke (IS). Conventional imaging poorly reflects plaque activity, whereas arterial wall enhancement on high-resolution MR vessel-wall imaging (HRMR-VWI) may serve as a marker of vascular disease activity. This study investigated the clinical, laboratory, and imaging factors associated with intracranial arterial wall enhancement and its value as an imaging biomarker of atherosclerotic burden. This single-center retrospective study included 470 ICAS-IS patients who underwent HRMR-VWI between March 2017 and July 2020. Enhancement grades (0-2) of culprit arteries were assessed. Clinical, biochemical, and imaging variables were compared across grades, and multinomial logistic regression identified independent predictors of enhancement severity. Among 470 patients (mean age 62.7 ± 10.6 years; 73.2% male), 78.5% showed intracranial arterial enhancement (grade ≥1), and 48.7% had grade 2 enhancement. Independent predictors of higher enhancement grades included the total number of stenotic vessels (grade 1 vs. 0: OR = 2.33; grade 2 vs. 0: OR = 2.09), number of enhanced vessels (grade 1 vs. 0: OR = 0.60; grade 2 vs. 0: OR = 0.63), presence of culprit-artery stenosis (grade 1 vs. 0: OR = 0.07; grade 2 vs. 0: OR= 0.03), and large-artery atherosclerosis (LAA) subtype (grade 1 vs. 0: OR = 4.44; grade 2 vs. 0: OR = 9.40; all P < 0.001). Non-stenotic enhancement occurred in 11.9% of patients. Intracranial arterial wall enhancement on HRMR-VWI is closely related to stenotic burden and shows a strong association with the LAA subtype. Enhancement grading may serve as a noninvasive imaging biomarker for evaluating disease activity and improving stroke subtype classification.
Indexed as
Identifiers
41348180What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.